Fernando Rodrigues Sells 5,677 Shares of Teladoc Health (NYSE:TDOC) Stock

Teladoc Health, Inc. (NYSE:TDOC) insider Fernando Rodrigues sold 5,677 shares of the stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $43,315.51. Following the transaction, the insider owned 9,572 shares in the company, valued at $73,034.36. This trade represents a 37.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Teladoc Health Stock Performance

NYSE TDOC opened at $7.29 on Friday. The business’s 50-day moving average price is $6.17 and its 200 day moving average price is $6.22. Teladoc Health, Inc. has a twelve month low of $4.40 and a twelve month high of $9.77. The company has a market capitalization of $1.32 billion, a PE ratio of -7.51 and a beta of 2.14. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.75.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, April 29th. The health services provider reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.01). The firm had revenue of $613.85 million during the quarter, compared to analysts’ expectations of $611.04 million. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.The business’s revenue for the quarter was down 2.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.53) earnings per share. Teladoc Health has set its FY 2026 guidance at -1.050–0.750 EPS and its Q2 2026 guidance at -0.300–0.200 EPS. On average, research analysts predict that Teladoc Health, Inc. will post -0.91 earnings per share for the current year.

Institutional Investors Weigh In On Teladoc Health

Large investors have recently modified their holdings of the stock. Allianz Asset Management GmbH grew its stake in shares of Teladoc Health by 189.2% in the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock valued at $12,518,000 after buying an additional 1,059,458 shares in the last quarter. Vanguard Group Inc. grew its stake in Teladoc Health by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock valued at $169,372,000 after purchasing an additional 891,732 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new stake in Teladoc Health during the 3rd quarter valued at approximately $7,576,000. Tejara Capital Ltd acquired a new stake in Teladoc Health during the 4th quarter valued at approximately $1,114,000. Finally, Monaco Asset Management SAM grew its stake in Teladoc Health by 159.2% during the 4th quarter. Monaco Asset Management SAM now owns 1,956,947 shares of the health services provider’s stock valued at $13,699,000 after purchasing an additional 1,201,947 shares in the last quarter. Institutional investors and hedge funds own 76.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TDOC. Piper Sandler restated an “overweight” rating and issued a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a report on Thursday, February 26th. Citigroup raised their price objective on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a report on Tuesday, May 5th. Bank of America upgraded Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price objective on the stock in a report on Thursday, February 26th. Oppenheimer cut their price objective on Teladoc Health from $12.00 to $7.00 and set an “outperform” rating on the stock in a report on Tuesday, March 3rd. Finally, BMO Capital Markets cut their price objective on Teladoc Health from $8.00 to $5.00 and set a “market perform” rating on the stock in a report on Thursday, February 26th. Five investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $7.43.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.